Moss v. Walgreen Co.

765 F. Supp. 2d 1363, 74 U.C.C. Rep. Serv. 2d (West) 103, 2011 U.S. Dist. LEXIS 22912, 2011 WL 832432
CourtDistrict Court, S.D. Florida
DecidedMarch 8, 2011
DocketCase 10-62089-CIV
StatusPublished
Cited by4 cases

This text of 765 F. Supp. 2d 1363 (Moss v. Walgreen Co.) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Moss v. Walgreen Co., 765 F. Supp. 2d 1363, 74 U.C.C. Rep. Serv. 2d (West) 103, 2011 U.S. Dist. LEXIS 22912, 2011 WL 832432 (S.D. Fla. 2011).

Opinion

ORDER DENYING MOTION TO DISMISS

JAMES I. COHN, District Judge.

THIS CAUSE is before the Court upon Defendant’s Motion to Dismiss Plaintiffs Complaint [DE 20] (“Motion to Dismiss”). The Court has considered the Complaint [DE 1], the Motion to Dismiss, the Memorandum of Law in Support of Defendant’s Motion to Dismiss [DE 21], Plaintiffs response [DE 30], Defendant’s reply [DE 37], and is otherwise advised in the premises.

I. INTRODUCTION

Plaintiff Howard Moss commenced this action on October 29, 2010, on behalf of himself and all others similarly situated against Defendant Walgreen Co. His Complaint alleges two counts: (1) violations of *1365 the Florida Deceptive and Unfair Trade Practices Act, Fla. Stat. § 501.201 et seq. (“FDUTPA”) and (2) breach of express warranty.

Defendant develops and markets health care products for consumers, including mouth rinses. Defendant sells different varieties of mouth rinses, including Walgreens Antiseptic Mouth Rinse (‘Walgreens Original”) and Walgreens Full Action Mouth Rinse (“Full Action”). Plaintiff alleges that Defendant has promoted Full Action as having certain benefits, including the following: “Full action, Freshens Breath, Restores Enamel, Helps Strengthen Teeth, Helps kill germs that cause bad breadth [sic] and Helps fight visible plaque above the gum line.” DE 1 ¶ 4. Plaintiff alleges that Full Action’s labeling claims are misleading and deceptive.

Specifically, Plaintiff alleges that Defendant does not possess or rely upon a reasonable basis to substantiate the claims that Full Action removes plaque above the gum line or promotes healthy gums. Id. ¶ 11. Plaintiff therefore contends that Defendant’s representations are misleading, false, and reasonably likely to deceive the public. Id. Plaintiff also alleges that as a result of the misleading messages, Defendant has charged a significant price premium for Full Action. Id. ¶ 14.

According to Plaintiff, he was exposed to Full Action advertising claims, purchased Full Action, and suffered injury in fact and lost money as a result of the unfair trade practices. Id. ¶ 17. Plaintiff brings this action on behalf of himself and other similarly situated consumers who purchase Full Action in the state of Florida in order to halt the dissemination of the false and misleading advertising message, correct the false and misleading perception Defendant has created in the minds of consumers, and to obtain redress for those who have purchased Full Action. Id. ¶ 16. On January 3, 2011, Defendant filed the Motion to Dismiss for failure to state a claim upon which relief can be granted pursuant to Federal Rules of Civil Procedure 12(b)(1) and 12(b)(6).

II. LEGAL STANDARD

Under Federal Rule of Civil Procedure 12(b)(6), a court shall grant a motion to dismiss where, based upon a dispositive issue of law, the factual allegations of the complaint cannot support the asserted cause of action. Glover v. Liggett Group, Inc., 459 F.3d 1304, 1308 (11th Cir.2006). Indeed, “[flactual allegations must be enough to raise a right to relief above the speculative level.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007). Thus, a complaint must contain “sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’ ” Ashcroft v. Iqbal, — U.S. -, 129 S.Ct. 1937, 1949, 173 L.Ed.2d 868 (2009) (quoting Twombly, 550 U.S. at 570, 127 S.Ct. 1955).

Nonetheless, a complaint must be liberally construed, assuming the facts alleged therein as true and drawing all reasonable inferences from those facts in the plaintiffs favor. Twombly, 550 U.S. at 555, 127 S.Ct. 1955. A complaint should not be dismissed simply because the court is doubtful that the plaintiff will be able to prove all of the necessary factual allegations. Id. Accordingly, a well pleaded complaint will survive a motion to dismiss “even if it appears ‘that a recovery is very remote and unlikely.’ ” Id. at 556, 127 S.Ct. 1955 (quoting Scheuer v. Rhodes, 416 U.S. 232, 236, 94 S.Ct. 1683, 40 L.Ed.2d 90 (1974)).

III. ANALYSIS

Defendant moves to dismiss the Complaint on the following grounds: (A) Plaintiff cannot base his claims on an alleged violation of the Food, Drug, and Cosmetic *1366 Act, 21 U.S.C. §§ 301 et seq. (“FDCA”), and (B) Plaintiff has failed to allege sufficient facts to sustain his FDUTPA and breach of warranty claims.

A. The FDCA Does Not Preempt Plaintiff’s Claims

Defendant argues that Plaintiff cannot base his claims on an allegation that Full Action’s labeling violates the FDCA. Specifically, Defendant asserts that the FDCA is a federal statute for which no private right of action exists. See 21 U.S.C. § 337(a) (“[A]ll such proceedings for the enforcement, or to restrain violations, of this chapter shall be by and in the name of the United States.”). Defendant further asserts that the FDCA preempts claims brought under state unfair competition laws that are predicated on violations of the FDCA. See DE 21 (citing In re Epogen & Aranesp Off-Label Mktg. & Sales Practices Litig., 590 F.Supp.2d 1282, 1290-91 (C.D.Cal.2008) (dismissing Plaintiffs’ suit after finding it was “largely an attempt to bring a private cause of action for violations of the FDCA.”); Andrx Pharms., Inc. v. Biovail Corp., 175 F.Supp.2d 1362, 1369-70 (S.D.Fla.2001)). Defendant maintains that Plaintiffs allegation regarding Full Action’s ability (or alleged inability) to fight plaque is predicated solely on a letter that the FDA sent to Defendant on September 27, 2010 (“FDA Letter”).

According to the allegations in the Complaint, the FDA Letter reflects the FDA’s determination that if Full Action fights plaque above the gum line, Full Action is a drug subject to regulation by the FDA. DE 1 ¶ 20. The FDA Letter also asserts that to the extent Full Action is to be used to prevent or mitigate disease or to affect the structure or function of the body by preventing or removing plaque and preventing gum disease, it would be a misbranded product. Id. ¶¶24.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Phelps v. Hormel Foods Corp.
244 F. Supp. 3d 1312 (S.D. Florida, 2017)
In re Colgate-Polmolive MDL
2013 DNH 049 (D. New Hampshire, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
765 F. Supp. 2d 1363, 74 U.C.C. Rep. Serv. 2d (West) 103, 2011 U.S. Dist. LEXIS 22912, 2011 WL 832432, Counsel Stack Legal Research, https://law.counselstack.com/opinion/moss-v-walgreen-co-flsd-2011.